| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 3,550 | 150 | 0 | 20,100 | 0 |
| Sales Growth | +2,266.65% | unch | -100.00% | unch | -100.00% |
| Net Income | -187,350 | -152,990 | -104,680 | -58,740 | -45,360 |
| Net Income Growth | -22.46% | -46.15% | -78.21% | -29.50% | -267.59% |
Keros Therapeutics Inc (KROS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
11.44 +0.02 (+0.18%) 03/20/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 11.44 unch (unch) 16:01 ET
for Thu, Mar 20th, 2025
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.
Fiscal Year End Date: 12/31